;PMID: 11054718
;source_file_727.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..195] = [t:37..195]
;2)section:[e:199..285] = [t:199..285]
;3)section:[e:289..395] = [t:289..395]
;4)sentence:[e:399..576] = [t:399..576]
;5)sentence:[e:577..671] = [t:577..671]
;6)sentence:[e:672..744] = [t:672..744]
;7)sentence:[e:745..896] = [t:745..896]
;8)sentence:[e:897..1124] = [t:897..1124]
;9)sentence:[e:1125..1307] = [t:1125..1307]
;10)sentence:[e:1308..1457] = [t:1308..1457]
;11)sentence:[e:1458..1541] = [t:1458..1541]
;12)sentence:[e:1542..1688] = [t:1542..1688]
;13)sentence:[e:1689..1869] = [t:1689..1869]
;14)sentence:[e:1870..2119] = [t:1870..2119]
;15)sentence:[e:2120..2321] = [t:2120..2321]
;16)section:[e:2322..2360] = [t:2322..2360]
;17)section:[e:2364..2409] = [t:2364..2409]

;section 0 Span:0..32
;J Pathol  2000 Nov;192(3):342-50
(SEC
  (FRAG (DT:[0..1] J) (NNP:[2..8] Pathol) (CD:[10..14] 2000)
        (CC:[15..23] Nov;192-LRB-) (CD:[23..24] 3) (-RRB-:[24..25] -RRB-)
        (CD:[25..29] :342) (::[29..30] -) (CD:[30..32] 50)))

;sentence 1 Span:37..195
;Prognostic value of the preserved expression of the E-cadherin and catenin 
;families of adhesion molecules and of beta-catenin mutations in synovial 
;sarcoma.
;[89..99]:gene-protein:"E-cadherin"
;[104..111]:gene-protein:"catenin"
;[151..163]:gene-rna:"beta-catenin"
;[177..194]:malignancy:"synovial  sarcoma"
(SENT
  (NP-HLN
    (NP (JJ:[37..47] Prognostic) (NN:[48..53] value))
    (PP
      (PP (IN:[54..56] of)
        (NP
          (NP (DT:[57..60] the) (VBN:[61..70] preserved)
              (NN:[71..81] expression))
          (PP (IN:[82..84] of)
            (NP
              (NP (DT:[85..88] the)
                (NML
                  (NML (NN:[89..99] E-cadherin)
                    (NML-1 (-NONE-:[99..99] *P*)))
                  (CC:[100..103] and)
                  (NML (NN:[104..111] catenin)
                    (NML-1 (NNS:[113..121] families)))))
              (PP (IN:[122..124] of)
                (NP (NN:[125..133] adhesion) (NNS:[134..143] molecules)))))))
      (CC:[144..147] and)
      (PP (IN:[148..150] of)
        (NP (NN:[151..163] beta-catenin) (NNS:[164..173] mutations))))
    (PP (IN:[174..176] in)
      (NP (JJ:[177..185] synovial) (NN:[187..194] sarcoma)))
    (.:[194..195] .)))

;section 2 Span:199..285
;Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, Iwamoto Y, 
;Tsuneyoshi M.
(SEC
  (FRAG (NNP:[199..204] Saito) (NNP:[205..206] T) (,:[206..207] ,)
        (NNP:[208..211] Oda) (NNP:[212..213] Y) (,:[213..214] ,)
        (NNP:[215..223] Sakamoto) (NNP:[224..225] A) (,:[225..226] ,)
        (NNP:[227..233] Tamiya) (NNP:[234..236] S,) (NNP:[237..245] Kinukawa)
        (NNP:[246..247] N) (,:[247..248] ,) (NNP:[249..256] Hayashi)
        (NNP:[257..258] K) (,:[258..259] ,) (NNP:[260..267] Iwamoto)
        (NNP:[268..269] Y) (,:[269..270] ,) (NNP:[272..282] Tsuneyoshi)
        (NNP:[283..285] M.)))

;section 3 Span:289..395
;Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu
; University, Fukuoka, Japan.
(SEC
  (FRAG (NNP:[289..299] Department) (IN:[300..302] of) (NNP:[303..311] Anatomic)
        (NNP:[312..321] Pathology) (,:[321..322] ,) (NNP:[323..331] Graduate)
        (NNP:[332..338] School) (IN:[339..341] of) (NNP:[342..349] Medical)
        (NNPS:[350..358] Sciences) (,:[358..359] ,) (NNP:[360..366] Kyushu)
        (NNP:[368..378] University) (,:[378..379] ,) (NNP:[380..387] Fukuoka)
        (,:[387..388] ,) (NNP:[389..394] Japan) (.:[394..395] .)))

;sentence 4 Span:399..576
;This study addresses the immunohistochemical expression of the E-cadherin and
; catenin families and mutations of the beta-catenin gene detected by PCR-SSCP
;in  synovial sarcoma.
;[462..472]:gene-protein:"E-cadherin"
;[478..485]:gene-protein:"catenin"
;[516..528]:gene-rna:"beta-catenin"
;[559..575]:malignancy:"synovial sarcoma"
(SENT
  (S
    (NP-SBJ (DT:[399..403] This) (NN:[404..409] study))
    (VP (VBZ:[410..419] addresses)
      (NP
        (NP
          (NP (DT:[420..423] the) (JJ:[424..443] immunohistochemical)
              (NN:[444..454] expression))
          (PP (IN:[455..457] of)
            (NP (DT:[458..461] the)
              (NML
                (NML (NN:[462..472] E-cadherin)
                  (NML-1 (-NONE-:[472..472] *P*)))
                (CC:[473..476] and)
                (NML (NN:[478..485] catenin)
                  (NML-1 (NNS:[486..494] families)))))))
        (CC:[495..498] and)
        (NP
          (NP
            (NP (NNS:[499..508] mutations))
            (PP (IN:[509..511] of)
              (NP (DT:[512..515] the) (NN:[516..528] beta-catenin)
                  (NN:[529..533] gene))))
          (VP (VBN:[534..542] detected)
            (NP (-NONE-:[542..542] *))
            (PP-MNR (IN:[543..545] by)
              (NP (NN:[546..549] PCR) (HYPH:[549..550] -) (NN:[550..554] SSCP))))))
      (PP (IN:[555..557] in)
        (NP (JJ:[559..567] synovial) (NN:[568..575] sarcoma))))
    (.:[575..576] .)))

;sentence 5 Span:577..671
;Immunohistochemical analysis was performed for 72 cases, with  follow-up data
;available on 62.
(SENT
  (S
    (NP-SBJ-1 (JJ:[577..596] Immunohistochemical) (NN:[597..605] analysis))
    (VP (VBD:[606..609] was)
      (VP (VBN:[610..619] performed)
        (NP-1 (-NONE-:[619..619] *))
        (PP (IN:[620..623] for)
          (NP (CD:[624..626] 72) (NNS:[627..632] cases)))
        (,:[632..633] ,)
        (PP (IN:[634..638] with)
          (S
            (NP-SBJ
              (ADJP (VB:[640..646] follow) (HYPH:[646..647] -)
                    (RP:[647..649] up))
              (NNS:[650..654] data))
            (ADJP-PRD (JJ:[655..664] available)
              (PP (IN:[665..667] on)
                (NP (CD:[668..670] 62))))))))
    (.:[670..671] .)))

;sentence 6 Span:672..744
;The prognostic value of the expression of these  proteins was evaluated.
;[721..729]:gene-protein:"proteins"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[672..675] The) (JJ:[676..686] prognostic) (NN:[687..692] value))
      (PP (IN:[693..695] of)
        (NP
          (NP (DT:[696..699] the) (NN:[700..710] expression))
          (PP (IN:[711..713] of)
            (NP (DT:[714..719] these) (NNS:[721..729] proteins))))))
    (VP (VBD:[730..733] was)
      (VP (VBN:[734..743] evaluated)
        (NP-1 (-NONE-:[743..743] *))))
    (.:[743..744] .)))

;sentence 7 Span:745..896
;Reduced immunoreactivity for E-cadherin and  alpha-catenin was significantly
;correlated with a poor survival rate (p=0.0040  and 0.0053, respectively).
;[774..784]:gene-protein:"E-cadherin"
;[790..803]:gene-protein:"alpha-catenin"
(SENT
  (S
    (NP-SBJ-1
      (NP (VBN:[745..752] Reduced) (NN:[753..769] immunoreactivity))
      (PP (IN:[770..773] for)
        (NP (NN:[774..784] E-cadherin) (CC:[785..788] and)
            (NN:[790..803] alpha-catenin))))
    (VP (VBD:[804..807] was)
      (ADVP (RB:[808..821] significantly))
      (VP (VBN:[822..832] correlated)
        (NP-1 (-NONE-:[832..832] *))
        (PP-CLR (IN:[833..837] with)
          (NP (DT:[838..839] a) (JJ:[840..844] poor) (NN:[845..853] survival)
              (NN:[854..858] rate)
            (PRN (-LRB-:[859..860] -LRB-)
              (S
                (NP-SBJ (NN:[860..861] p))
                (VP (SYM:[861..862] =)
                  (NP (CD:[862..868] 0.0040) (CC:[870..873] and)
                      (CD:[874..880] 0.0053))
                  (,:[880..881] ,)
                  (ADVP (RB:[882..894] respectively))))
              (-RRB-:[894..895] -RRB-))))))
    (.:[895..896] .)))

;sentence 8 Span:897..1124
;According to multivariate analysis, low AJC stage  (stages I and II:
;p<0.0001), the preservation of alpha-catenin expression  (p=0.0001), and a
;low necrotic rate (<50%: p=0.0139) were independent favourable  prognostic
;factors.
;[997..1010]:gene-protein:"alpha-catenin"
(SENT
  (S
    (PP (VBG:[897..906] According)
      (PP (TO:[907..909] to)
        (NP (JJ:[910..922] multivariate) (NN:[923..931] analysis))))
    (,:[931..932] ,)
    (NP-SBJ
      (NP (JJ:[933..936] low) (NN:[937..940] AJC) (NN:[941..946] stage)
        (PRN (-LRB-:[948..949] -LRB-)
          (FRAG
            (NP
              (NP
                (NML-1 (NNS:[949..955] stages))
                (CD:[956..957] I))
              (CC:[958..961] and)
              (NP
                (NML-1 (-NONE-:[961..961] *P*))
                (CD:[962..964] II)))
            (::[964..965] :)
            (S
              (NP-SBJ (NN:[966..967] p))
              (VP (SYM:[967..968] <)
                (NP (CD:[968..974] 0.0001)))))
          (-RRB-:[974..975] -RRB-)))
      (,:[975..976] ,)
      (NP
        (NP (DT:[977..980] the) (NN:[981..993] preservation))
        (PP (IN:[994..996] of)
          (NP (NN:[997..1010] alpha-catenin) (NN:[1011..1021] expression)
            (PRN (-LRB-:[1023..1024] -LRB-)
              (S
                (NP-SBJ (NN:[1024..1025] p))
                (VP (SYM:[1025..1026] =)
                  (NP (CD:[1026..1032] 0.0001))))
              (-RRB-:[1032..1033] -RRB-)))))
      (,:[1033..1034] ,) (CC:[1035..1038] and)
      (NP (DT:[1039..1040] a) (JJ:[1041..1044] low) (JJ:[1045..1053] necrotic)
          (NN:[1054..1058] rate)
        (PRN (-LRB-:[1059..1060] -LRB-)
          (FRAG
            (NP
              (QP (SYM:[1060..1061] <) (CD:[1061..1063] 50))
              (NN:[1063..1064] %))
            (::[1064..1065] :)
            (S
              (NP-SBJ (NN:[1066..1067] p))
              (VP (SYM:[1067..1068] =)
                (NP (CD:[1068..1074] 0.0139)))))
          (-RRB-:[1074..1075] -RRB-))))
    (VP (VBD:[1076..1080] were)
      (NP-PRD (JJ:[1081..1092] independent) (JJ:[1093..1103] favourable)
              (JJ:[1105..1115] prognostic) (NNS:[1116..1123] factors)))
    (.:[1123..1124] .)))

;sentence 9 Span:1125..1307
;Widespread aberrant staining of beta-catenin protein within  cytoplasm and/or
;nuclei was observed in 28 cases (38.9%) and was significantly  correlated
;with poor survival (p=0.0122).
;[1157..1169]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1125..1135] Widespread) (JJ:[1136..1144] aberrant)
          (NN:[1145..1153] staining))
      (PP (IN:[1154..1156] of)
        (NP (NN:[1157..1169] beta-catenin) (NN:[1170..1177] protein)))
      (PP (IN:[1178..1184] within)
        (NP (NN:[1186..1195] cytoplasm) (CC:[1196..1202] and/or)
            (NNS:[1203..1209] nuclei))))
    (VP
      (VP (VBD:[1210..1213] was)
        (VP (VBN:[1214..1222] observed)
          (NP-1 (-NONE-:[1222..1222] *))
          (PP (IN:[1223..1225] in)
            (NP (CD:[1226..1228] 28) (NNS:[1229..1234] cases)
              (PRN (-LRB-:[1235..1236] -LRB-)
                (NP (CD:[1236..1240] 38.9) (NN:[1240..1241] %))
                (-RRB-:[1241..1242] -RRB-))))))
      (CC:[1243..1246] and)
      (VP (VBD:[1247..1250] was)
        (ADVP (RB:[1251..1264] significantly))
        (VP (VBN:[1266..1276] correlated)
          (NP-1 (-NONE-:[1276..1276] *))
          (PP-CLR (IN:[1277..1281] with)
            (NP (JJ:[1282..1286] poor) (NN:[1287..1295] survival)))
          (PRN (-LRB-:[1296..1297] -LRB-)
            (S
              (NP-SBJ (NN:[1297..1298] p))
              (VP (SYM:[1298..1299] =)
                (NP (CD:[1299..1305] 0.0122))))
            (-RRB-:[1305..1306] -RRB-)))))
    (.:[1306..1307] .)))

;sentence 10 Span:1308..1457
;In addition, there was a trend towards  a correlation between widespread
;aberrant staining of beta-catenin and the MIB-1  labelling index (p=0.0535).
;[1402..1414]:gene-protein:"beta-catenin"
(SENT
  (S
    (PP (IN:[1308..1310] In)
      (NP (NN:[1311..1319] addition)))
    (,:[1319..1320] ,)
    (NP-SBJ (EX:[1321..1326] there))
    (VP (VBD:[1327..1330] was)
      (NP-PRD
        (NP (DT:[1331..1332] a) (NN:[1333..1338] trend))
        (PP (IN:[1339..1346] towards)
          (NP
            (NP (DT:[1348..1349] a) (NN:[1350..1361] correlation))
            (PP (IN:[1362..1369] between)
              (NP
                (NP
                  (NP (JJ:[1370..1380] widespread) (JJ:[1381..1389] aberrant)
                      (NN:[1390..1398] staining))
                  (PP (IN:[1399..1401] of)
                    (NP (NN:[1402..1414] beta-catenin))))
                (CC:[1415..1418] and)
                (NP (DT:[1419..1422] the) (NN:[1423..1428] MIB-1)
                    (NN:[1430..1439] labelling) (NN:[1440..1445] index))))
            (PRN (-LRB-:[1446..1447] -LRB-)
              (S
                (NP-SBJ (NN:[1447..1448] p))
                (VP (SYM:[1448..1449] =)
                  (NP (CD:[1449..1455] 0.0535))))
              (-RRB-:[1455..1456] -RRB-))))))
    (.:[1456..1457] .)))

;sentence 11 Span:1458..1541
;Mutational analysis of exon 3 of the beta-catenin  gene was performed for 49
;cases.
;[1481..1487]:variation-location:"exon 3"
;[1495..1507]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1458..1468] Mutational) (NN:[1469..1477] analysis))
      (PP (IN:[1478..1480] of)
        (NP
          (NP (NN:[1481..1485] exon) (CD:[1486..1487] 3))
          (PP (IN:[1488..1490] of)
            (NP (DT:[1491..1494] the) (NN:[1495..1507] beta-catenin)
                (NN:[1509..1513] gene))))))
    (VP (VBD:[1514..1517] was)
      (VP (VBN:[1518..1527] performed)
        (NP-1 (-NONE-:[1527..1527] *))
        (PP (IN:[1528..1531] for)
          (NP (CD:[1532..1534] 49) (NNS:[1535..1540] cases)))))
    (.:[1540..1541] .)))

;sentence 12 Span:1542..1688
;Nucleotide sequencing analysis revealed that  four (8.2%) contained point
;mutations (three in codon 32, GAC to TAC; one in  codon 37, TCT to TTT).
;[1610..1625]:variation-type:"point mutations"
;[1636..1644]:variation-location:"codon 32"
;[1646..1649]:variation-state-original:"GAC"
;[1653..1656]:variation-state-altered:"TAC"
;[1666..1674]:variation-location:"codon 37"
;[1676..1679]:variation-state-original:"TCT"
;[1683..1686]:variation-state-altered:"TTT"
(SENT
  (S
    (NP-SBJ (NN:[1542..1552] Nucleotide) (NN:[1553..1563] sequencing)
            (NN:[1564..1572] analysis))
    (VP (VBD:[1573..1581] revealed)
      (SBAR (IN:[1582..1586] that)
        (S
          (NP-SBJ (CD:[1588..1592] four)
            (PRN (-LRB-:[1593..1594] -LRB-)
              (NP (CD:[1594..1597] 8.2) (NN:[1597..1598] %))
              (-RRB-:[1598..1599] -RRB-)))
          (VP (VBD:[1600..1609] contained)
            (NP
               (NN:[1610..1615] point) (NNS:[1616..1625] mutations)
              (PRN (-LRB-:[1626..1627] -LRB-)
                (NP
                  (NP
                    (NP
                      (NP (CD:[1627..1632] three))
                      (PP-LOC (IN:[1633..1635] in)
                        (NP (NN:[1636..1641] codon) (CD:[1642..1644] 32))))
                    (,:[1644..1645] ,)
                    (NP
                      (NP (NN:[1646..1649] GAC))
                      (PP (TO:[1650..1652] to)
                        (NP (NN:[1653..1656] TAC)))))
                  (::[1656..1657] ;)
                  (NP
                    (NP
                      (NP (CD:[1658..1661] one))
                      (PP-LOC (IN:[1662..1664] in)
                        (NP (NN:[1666..1671] codon) (CD:[1672..1674] 37))))
                    (,:[1674..1675] ,)
                    (NP
                      (NP (NN:[1676..1679] TCT))
                      (PP (TO:[1680..1682] to)
                        (NP (NN:[1683..1686] TTT))))))
                (-RRB-:[1686..1687] -RRB-)))))))
    (.:[1687..1688] .)))

;sentence 13 Span:1689..1869
;Survival data were available for three out of four cases  with beta-catenin
;mutations; two of these patients died within 1 year (died of  disease at 6
;and 11 months, respectively).
;[1752..1764]:gene-rna:"beta-catenin"
(SENT
  (S
    (S
      (NP-SBJ (NN:[1689..1697] Survival) (NNS:[1698..1702] data))
      (VP (VBD:[1703..1707] were)
        (ADJP-PRD (JJ:[1708..1717] available)
          (PP (IN:[1718..1721] for)
            (NP
              (NP (CD:[1722..1727] three))
              (PP (IN:[1728..1731] out)
                (PP (IN:[1732..1734] of)
                  (NP
                    (NP (CD:[1735..1739] four) (NNS:[1740..1745] cases))
                    (PP (IN:[1747..1751] with)
                      (NP (NN:[1752..1764] beta-catenin)
                          (NNS:[1765..1774] mutations)))))))))))
    (::[1774..1775] ;)
    (S
      (NP-SBJ
        (NP (CD:[1776..1779] two))
        (PP (IN:[1780..1782] of)
          (NP (DT:[1783..1788] these) (NNS:[1789..1797] patients))))
      (VP (VBD:[1798..1802] died)
        (PP-TMP (IN:[1803..1809] within)
          (NP (CD:[1810..1811] 1) (NN:[1812..1816] year)))
        (PRN (-LRB-:[1817..1818] -LRB-)
          (VP (VBN:[1818..1822] died)
            (PP-CLR (IN:[1823..1825] of)
              (NP (NN:[1827..1834] disease)))
            (PP-TMP (IN:[1835..1837] at)
              (NP
                (NP (CD:[1838..1839] 6)
                  (NML-1 (-NONE-:[1839..1839] *P*)))
                (CC:[1840..1843] and)
                (NP (CD:[1844..1846] 11)
                  (NML-1 (NNS:[1847..1853] months)))))
            (,:[1853..1854] ,)
            (ADVP (RB:[1855..1867] respectively)))
          (-RRB-:[1867..1868] -RRB-))))
    (.:[1868..1869] .)))

;sentence 14 Span:1870..2119
;These results suggest that E-cadherin  and alpha-catenin undertake important
;roles as intercellular adhesion molecules;  their preserved expression is
;associated with a better overall survival rate in  synovial sarcoma and may
;have prognostic value.
;[1897..1907]:gene-protein:"E-cadherin"
;[1913..1926]:gene-protein:"alpha-catenin"
;[2072..2088]:malignancy:"synovial sarcoma"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1870..1875] These) (NNS:[1876..1883] results))
      (VP (VBP:[1884..1891] suggest)
        (SBAR (IN:[1892..1896] that)
          (S
            (NP-SBJ (NN:[1897..1907] E-cadherin) (CC:[1909..1912] and)
                    (NN:[1913..1926] alpha-catenin))
            (VP (VBP:[1927..1936] undertake)
              (NP
                (NP (JJ:[1937..1946] important) (NNS:[1947..1952] roles))
                (PP (IN:[1953..1955] as)
                  (NP (JJ:[1956..1969] intercellular) (NN:[1970..1978] adhesion)
                      (NNS:[1979..1988] molecules)))))))))
    (::[1988..1989] ;)
    (S
      (NP-SBJ-1 (PRP$:[1991..1996] their) (VBN:[1997..2006] preserved)
                (NN:[2007..2017] expression))
      (VP
        (VP (VBZ:[2018..2020] is)
          (VP (VBN:[2021..2031] associated)
            (NP-1 (-NONE-:[2031..2031] *))
            (PP-CLR (IN:[2032..2036] with)
              (NP (DT:[2037..2038] a) (JJR:[2039..2045] better)
                  (JJ:[2046..2053] overall) (NN:[2054..2062] survival)
                  (NN:[2063..2067] rate)))
            (PP (IN:[2068..2070] in)
              (NP (JJ:[2072..2080] synovial) (NN:[2081..2088] sarcoma)))))
        (CC:[2089..2092] and)
        (VP (MD:[2093..2096] may)
          (VP (VB:[2097..2101] have)
            (NP (JJ:[2102..2112] prognostic) (NN:[2113..2118] value))))))
    (.:[2118..2119] .)))

;sentence 15 Span:2120..2321
;Abnormal levels of beta-catenin,  with or without mutation, could contribute
;to the development and progression of  synovial sarcoma, through increasing
;the proliferative activity of the tumour  cells.
;[2139..2151]:gene-protein:"beta-catenin"
;[2170..2178]:variation-event:"mutation"
;[2236..2252]:malignancy:"synovial sarcoma"
;[2307..2320]:malignancy:"tumour  cells"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[2120..2128] Abnormal) (NNS:[2129..2135] levels))
      (PP (IN:[2136..2138] of)
        (NP (NN:[2139..2151] beta-catenin)))
      (,:[2151..2152] ,)
      (PP (IN:[2154..2158] with) (CC:[2159..2161] or) (IN:[2162..2169] without)
        (NP (NN:[2170..2178] mutation))))
    (,:[2178..2179] ,)
    (VP (MD:[2180..2185] could)
      (VP (VB:[2186..2196] contribute)
        (PP-CLR (TO:[2197..2199] to)
          (NP
            (NP (DT:[2200..2203] the) (NN:[2204..2215] development)
                (CC:[2216..2219] and) (NN:[2220..2231] progression))
            (PP (IN:[2232..2234] of)
              (NP (JJ:[2236..2244] synovial) (NN:[2245..2252] sarcoma)))))
        (,:[2252..2253] ,)
        (PP-MNR (IN:[2254..2261] through)
          (S-NOM
            (NP-SBJ (-NONE-:[2261..2261] *))
            (VP (VBG:[2262..2272] increasing)
              (NP
                (NP (DT:[2273..2276] the) (JJ:[2277..2290] proliferative)
                    (NN:[2291..2299] activity))
                (PP (IN:[2300..2302] of)
                  (NP (DT:[2303..2306] the)
                     (NN:[2307..2313] tumour) (NNS:[2315..2320] cells)))))))))
    (.:[2320..2321] .)))

;section 16 Span:2322..2360
;Copyright 2000 John Wiley & Sons, Ltd.
(SEC
  (FRAG (NN:[2322..2331] Copyright) (CD:[2332..2336] 2000)
        (NNP:[2337..2341] John) (NNP:[2342..2347] Wiley) (CC:[2348..2349] &)
        (NNP:[2350..2354] Sons) (,:[2354..2355] ,) (NNP:[2356..2360] Ltd.)))

;section 17 Span:2364..2409
;PMID: 11054718 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2364..2368] PMID) (::[2368..2369] :) (CD:[2370..2378] 11054718)
        (NN:[2379..2380] -LSB-) (NNP:[2380..2386] PubMed) (::[2387..2388] -)
        (NN:[2389..2396] indexed) (IN:[2397..2400] for)
        (NNP:[2401..2409] MEDLINE-RSB-)))
